Neumora Therapeutics, Inc. (NMRA)

NASDAQ: NMRA · IEX Real-Time Price · USD
+0.02 (0.18%)
At close: Sep 22, 2023, 4:00 PM
-0.32 (-2.90%)
After-hours: Sep 22, 2023, 7:23 PM EDT
Market Cap 1.68B
Revenue (ttm) n/a
Net Income (ttm) -131.66M
Shares Out 151.95M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 771,019
Open 11.01
Previous Close 11.01
Day's Range 10.47 - 11.62
52-Week Range 9.90 - 17.74
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 15, 2023

About NMRA

Neumora Therapeutics is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. We have rapidly scaled our therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. We expect to continue to progress the development of our pipeline wit... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2023
Employees 110
Stock Exchange NASDAQ
Ticker Symbol NMRA
Full Company Profile

Financial Performance

Financial Statements


Neumora Therapeutics Announces Pricing of Initial Public Offering

WATERTOWN, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (“Neumora”), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pr...

9 days ago - GlobeNewsWire

SoftBank-backed Neumora Therapeutics files paperwork for U.S. IPO

Neumora Therapeutics, a biopharmaceutical firm backed by biotech Amgen and Japans SoftBank , on Friday filed for an initial public offering of its shares in New York.

4 weeks ago - Reuters

Neumora Therapeutics IPO Registration Document (S-1)

Neumora Therapeutics has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC